文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

宫颈癌放疗开始前分期进展速度的器械变量分析

Pace of Cervical Cancer Stage Progression Prior to Radiation Therapy Initiation, an Instrumental Variable Analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-08-13

该前瞻性队列研究纳入2012至2019年在博茨瓦纳接受放疗的763例宫颈癌女性,利用季节性就医延迟作为器械变量,估计治疗延迟对分期进展的因果效应。结果显示宫颈癌分期平均每8.6周进展一次,HIV阳性者7.6周,阴性者8.7周;分期升高与生存时间缩短38%相关,建议诊断后4周内开始治疗。

要点

  • 宫颈癌分期平均每8.6周进展一次,HIV阳性者更快(7.6周)。
  • 分期升高与生存时间缩短38%相关(95%CI 33%-44%)。
  • 建议诊断后4周内开始放疗以降低分期进展风险。

核心结论

  • 常规护理中常见的适度治疗延迟与可测量的宫颈癌进展相关,可能降低生存。
  • 诊断后4周内开始治疗可最小化分期进展风险。

研究设计与样本

  • 前瞻性队列研究,纳入2012至2019年博茨瓦纳接受放疗的763例宫颈癌女性。
  • 采用基于季节性治疗可及性变异的器械变量方法,以诊断月份为自然变异来源。
  • 使用两阶段加权模型估计平均延迟和平均分期,并分析分期与总生存的关联。

主要发现

  • 延迟获取组平均治疗开始时间12.4周,常规获取组11.2周(器械变量偏F统计量13.1)。
  • 宫颈癌分期进展估计平均需8.6周(95%CI 7.1-10.9)。
  • 分期进展时间因HIV状态而异(P < .001):HIV阳性者7.6周(95%CI 6.4-9.2),HIV阴性者8.7周(95%CI 6.1-15.3)。
  • 分期升高与生存时间缩短38%相关(95%CI 33%-44%)。

关键数值与推荐

  • 宫颈癌分期进展平均时间8.6周(95%CI 7.1-10.9)。
  • HIV阳性者分期进展估计7.6周(95%CI 6.4-9.2),HIV阴性者8.7周(95%CI 6.1-15.3)。
  • 分期升高与生存时间缩短38%相关(95%CI 33%-44%)。
  • 推荐诊断后4周内开始治疗以最小化分期进展风险。

临床怎么用

  • 应尽量在宫颈癌诊断后4周内启动放疗,以减少分期进展和生存损失。
  • 对HIV阳性宫颈癌患者,因其分期进展可能更快,应优先安排及时治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In initiating radiation therapy for cervical cancer are common and may contribute to poorer outcomes. However, the pace of stage progression remains uncertain, limiting the development of quality targets and mitigation strategies. Delays in initiating radiation therapy for cervical cancer are common and contribute to poorer outcomes. We sought to estimate the pace of stage progression to guide development of quality targets and mitigation strategies. METHODS AND MATERIALS: We conducted a prospective cohort study of women with cervical cancer treated with radiation in Botswana between 2012 and 2019. We used an instrumental variable approach based on seasonal variation in access to treatment to estimate the causal effect of treatment delay on cancer stage progression. The month of cancer diagnosis served as a natural source of variation, with women diagnosed during end-of-year holiday disruptions (November-February) experiencing longer delays on average than women at other times of the year. Using two-stage weighted models of mean delay and mean cancer stage at time of treatment, we estimated the average time required for cervical cancer stage to progress (eg, IIIA and IIIB). To contextualize findings we examined the association between cancer stage at treatment initiation and overall survival. RESULTS: Among 763 eligible participants, 494 were diagnosed during routine access periods and 269 during delayed periods. The mean time to treatment initiation was longer (instrumental variable partial F-statistic 13.1) in the delayed-access group (12.4 weeks) compared with the routine access group (11.2 wk). The groups were otherwise well-balanced. In the primary analysis, cervical cancer stage progression was estimated to occur over a mean of 8.6 weeks (95% CI, 7.1-10.9). Modeled time to stage progression differed by HIV status (P < .001), with estimated 7.6 weeks (95% CI, 6.4-9.2) for women with HIV and 8.7 weeks (95% CI, 6.1-15.3) for women without HIV. Stage increase was associated with a 38% reduction in survival time (95% CI, 33%-44%). CONCLUSIONS: Modest treatment delays commonly encountered in routine care were associated with measurable cervical cancer progression, likely decreasing survival. Initiating treatment within 4 weeks from diagnosis minimizes the risk of stage progression.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sekar P, Vulysteke P, Ntloedibe T, et al. Pace of Cervical Cancer Stage Progression Prior to Radiation Therapy Initiation, an Instrumental Variable Analysis. Int J Radiat Oncol Biol Phys. 2026. PMID: 42586220. doi:10.1016/j.ijrobp.2026.07.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。